Basal cell carcinoma (BCC) is a common type of skin cancer that can be challenging to treat in advanced stages. Join Karl Lewis, MD, and Aleksandar Sekulic, MD, PhD, as they discuss the importance of the hedgehog pathway in the pathogenesis of BCC and the role of hedgehog inhibitors in advanced BCC. Evidence related to the safety and efficacy of the approved hedgehog inhibitors sonidegib and vismodegib is discussed, with recommendations for optimizing their use. Case studies are utilized to share the faculty’s experience in treating patients with hedgehog inhibitors, including strategies to manage resistance.
As in medicine generally, the management of patients with locally advanced basal cell carcinoma is rapidly evolving. To help clinicians keep abreast of new information, this CME activity will be updated 4 times through October 2021. The first update included new information released between February 17, 2021, and April 7, 2021. The second update includes new information released between April 8, 2021, and June 1, 2021. The third update includes new information released between June 1, 2021, and July 30, 2021.The fourth update includes new information published between August 1, 2021, and September 30, 2021.
2.00 AMA PRA Category 1 CreditsTM
This activity is intended for a national audience of oncologists, dermatologists, dermato-oncologists, and Mohs surgeons.
This activity is supported by an independent medical education grant from Regeneron Pharmaceuticals, Inc and Sanofi Genzyme.
Karl D. Lewis, MD
Associate Professor of Medicine
Division of Medical Oncology
University of Colorado
UCH - Cancer Center
Aleksandar Sekulic, MD, PhD
Deputy Director, Mayo Clinic Cancer Center
Associate Director, Center for Individualized Medicine
Vice Chair, Department of Dermatology
Chair, Cutaneous Oncology Disease Group
Mayo Clinic Scottsdale